In Denmark, Novozymes and Chr. Hansen have agreed to merge in a deal that would create a bioscience giant with over €3.5 billion ($3.7 billion) in annual sales and meet growing demand for scalable and sustainable biosolutions.
Novozymes is the world’s largest provider of enzyme and microbial technologies, and Chr. Hansen boasts over 145 years’ experience developing natural ingredient solutions for the food, nutritional, pharmaceutical, and agricultural industries. Half of the combined company’s portfolio will focus on enabling healthier lives and producing better foods. The other half will address reducing chemical use and targeting climate neutral practices.
Novo Holdings A/S, the largest shareholder in both Novozymes and Chr. Hansen, has affirmed its confidence in the two companies “being a perfect match,” according to a press statement. The deal is expected to close in the final quarter of 2023.